TriSalus Life Sciences (TLSI) financials · rev $45.2M
TriSalus Life Sciences (TLSI) rev $45.2M.
| Line | FY2025 | FY2024 | Pro (2 older periods with Lician Pro) |
|---|---|---|---|
| Revenue | $45.15M | $29.43M | |
| Cost of Revenue | $6.96M | $4.10M | |
| Gross Profit | $38.19M | $25.33M | |
| Operating Income | −$26.95M | −$36.16M | |
| Net Income | −$39.23M | −$30.05M | |
| EPS (Diluted) | −$1.84 | −$1.31 | |
| Unlock 5 years of statements: Lician Pro $149/yr | |||
| Line | FY2025 | FY2024 | Pro (3 older periods with Lician Pro) |
|---|---|---|---|
| Total Assets | $35.33M | $23.97M | |
| Current Assets | $32.24M | $20.67M | |
| Cash & Equivalents | $20.44M | $8.53M | |
| Inventory | $3.08M | $4.05M | |
| Total Liabilities | $69.19M | $49.87M | |
| Current Liabilities | $11.50M | $10.23M | |
| Long-term Debt | $33.05M | $22.08M | |
| Total Debt | $33.05M† | $22.08M† | |
| Shareholders' Equity | −$33.86M | −$25.89M | |
| Retained Earnings | −$330.58M | −$279.55M |
† Total Debt: Derived from long-term debt only (no total or short-term debt stored).
| Line | FY2025 | FY2024 | Pro (2 older periods with Lician Pro) |
|---|---|---|---|
| Operating Cash Flow | −$18.01M | −$40.84M | |
| CapEx | $918.00K | $345.00K | |
| Investing Cash Flow | −$838.00K | −$345.00K | |
| Financing Cash Flow | $30.76M | $37.94M | |
| Net Change in Cash | $11.91M | −$3.25M | |
| Free Cash Flow | −$18.93M | −$41.19M |
Source: Company filings with the SEC (EDGAR) · Latest period FY2025
FAQ
What is TLSI P/E and revenue?
TriSalus Life Sciences (TLSI) rev $45.2M.
What is TLSI revenue?
TriSalus Life Sciences last cached revenue is $45.2M (FY2025).
Is TLSI profitable?
TriSalus Life Sciences last cached net income is -$39.2M (FY2025).
What are TLSI total assets?
TriSalus Life Sciences last cached total assets are $35.3M (FY2025).
What is TLSI free cash flow?
TriSalus Life Sciences last cached free cash flow is -$18.9M (FY2025).
Not investment advice. Figures as reported in company filings, not a live feed.